Observational Study of SIROPSEDAL in Acute Cough
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age1+
SponsorLaboratoires Elerte
About this trial
This prospective, multicenter, observational post-market clinical follow-up study evaluates the performance and safety of SIROPSEDAL in children and adults with acute cough treated in routine clinical practice. Patients prescribed SIROPSEDAL independently of study participation will be followed for 7 +/- 1 days using patient-reported outcomes including a cough visual analog scale and the Cough Symptom Score.
Eligibility criteria
Qualifiers
Age greater than or equal to 1 year.
Acute cough evolving for less than 10 days.
Cough intensity VAS greater than 40/100.
SIROPSEDAL prescribed independently from study participation.
Disqualifiers
ACE inhibitor or sartan use.
Asthma or COPD.
Corticosteroids ongoing or within the previous 3 days.
Antibiotics ongoing or within the previous 3 days.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.
Multiples facilities Status unavailable Multiple Locations
France
FranceSponsors and collaborators
Laboratoires Elerte
Lead sponsor
Clin-Experts
Collaborator
Source ClinicalTrials.gov